Inhibition of the Proteasome Activity by Gallium(III) Complexes Contributes to Their Anti–Prostate Tumor Effects
Open Access
- 1 October 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (19), 9258-9265
- https://doi.org/10.1158/0008-5472.can-07-1813
Abstract
The investigation of metal-based complexes with potential antitumor activity has been of paramount importance in recent years due to the successful use of cisplatin against various cancers. Gallium(III) and subsequently developed gallium(III)-containing complexes have shown promising antineoplastic effects when tested in a host of malignancies, specifically in lymphomas and bladder cancer. However, the molecular mechanism responsible for their anticancer effect is yet to be fully understood. We report here for the first time that the proteasome is a molecular target for gallium complexes in a variety of prostate cancer cell lines and in human prostate cancer xenografts. We tested five gallium complexes (1–5) in which the gallium ion is bound to an NN′O asymmetrical ligand containing pyridine and substituted phenolate moieties in a 1:2 (M/L) ratio. We found that complex 5 showed superior proteasome inhibitory activity against both 26S proteasome (IC50, 17 μmol/L) and purified 20S (IC50, 16 μmol/L) proteasome. Consistently, this effect was associated with apoptosis induction in prostate cancer cells. Additionally, complex 5 was able to exert the same effect in vivo by inhibiting growth of PC-3 xenografts in mice (66%), which was associated with proteasome inhibition and apoptosis induction. Our results strongly suggest that gallium complexes, acting as potent proteasome inhibitors, have a great potential to be developed into novel anticancer drugs. [Cancer Res 2007;67(19):9258–65]Keywords
This publication has 27 references indexed in Scilit:
- Preclinical characterization of anticancer gallium(III) complexes: Solubility, stability, lipophilicity and binding to serum proteinsJournal of Inorganic Biochemistry, 2006
- Synthesis, Structure, and Anticancer Activity of Gallium(III) Complexes with Asymmetric Tridentate Ligands: Growth Inhibition and Apoptosis Induction of Cisplatin-Resistant Neuroblastoma CellsInorganic Chemistry, 2006
- United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior TherapyClinical Cancer Research, 2006
- Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors ? a CESAR study (Central European Society for Anticancer Drug Research ? EWInternational journal of clinical pharmacology and therapeutics, 2005
- Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosisFrontiers in Bioscience-Landmark, 2005
- Gallium nitrate for the treatment of non-Hodgkin’s lymphomaExpert Opinion on Investigational Drugs, 2004
- Proteasome Activity Is Required for Androgen Receptor Transcriptional Activity via Regulation of Androgen Receptor Nuclear Translocation and Interaction with Coregulators in Prostate Cancer CellsPublished by Elsevier BV ,2002
- Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27Science, 1995
- Ubiquitin, proteasomes, and the regulation of intracellular protein degradationCurrent Opinion in Cell Biology, 1995
- Gallium NitrateDrugs, 1991